September 29th 2023
Learn more about the in-depth topics covered in the September 2023 Frontline Forum BCC management supplement of Dermatology Times.
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Expert Illustrations and Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
Register Now!
Best Practice in the Multidisciplinary Care of the Patient with HS
View More
Addressing Challenges in the Management of HS in Special Populations
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Cases and Conversations™: Enhancing Diagnosis and Evaluation of Generalized Pustular Psoriasis in Advanced Practice Settings
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
Clinical ShowCase™ in Atopic Dermatitis: Personalized Management Plans for Pediatric Patients
View More
20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Facing the Changing Landscape for Neuromodulators and Dermal Fillers
View More
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care
View More
Study: Curcumin Nanoparticles as a Photoprotective Adjuvant
August 24th 2021Curcumin has a long history as an effective treatment for everything from chronic pain to skin infections. Nanoparticle encapsulation shows promise in meeting that challenge and opening the way for a safe, effective adjuvant to sunscreen.
FDA Grants Priority Review to Adjuvant Pembrolizumab for Stage II High-Risk Melanoma
August 6th 2021The FDA has granted priority review to a supplemental biologics license application for pembrolizumab for the use as an adjuvant treatment in adult and pediatric patients with stage IIB or IIC melanoma following complete resection.
Valisure CEO Shares Thoughts on Johnson & Johnson Sunscreen Recall
August 4th 2021In this video interview, David Light, CEO of Valisure, shares his thoughts on the recent sunscreen recall from Johnson & Johnson due to benzene contamination and reveals how the FDA and sun protection companies can make sure this never happens again.
Doctors Aim for Better Understanding of Pediatric Melanoma Through Registry
August 3rd 2021In this video interview, Alberto Pappo, MD, director, St. Jude Solid Tumor Division, discusses a registry he helped create aimed at helping physicians better understand pediatric melanoma called Molecular Analysis of Childhood MELanocytic Tumors (MACMEL).
Physician Provides Update on Benzene Contamination in Sunscreens
July 29th 2021In this exclusive video interview, Christopher Bunick, MD, PhD, gives Dermatology Times an update on benzene contamination being detected in various sunscreens and after-sun care products, as well as a recent recall by Johnson & Johnson.
Physician Weighs in on Sunscreen Contamination Controversy
May 28th 2021Christopher Bunick, MD, PhD, associate professor of dermatology, Yale University and Dermatology Times® editorial advisory board member, weighs in on a recent report revealing certain batches of various sunscreen and after-sun care products were contaminated with benzene, a carcinogen.
Valisure Highlights Controversy of Benzene Contamination in Sunscreen Products
May 26th 2021David Light, founder and CEO of Valisure, the independent lab that discovered the presence of benzene in multiple brands and batches of sunscreen, sits down with Dermatology Times to discuss the reports' findings and the impact this news will have on the sun protection industry.